Table 2.
Crude
|
Adjusted
|
PS matched
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | Events | (%) HR | 95% CI | HR | 95% CI | N | Events (%) | HR | 95% CI | ||
Whole sample | PEG | 429,430 | 1354 (0.3) | – | – | – | – | 121,203 | 283 (0.2) | – | – |
Sodium phosphate | 121,266 | 241 (0.2) | 0.63 | 0.55–0.72 | 0.86 | 0.75–0.99 | 121,203 | 241 (0.2) | 0.85 | 0.72–1.01 | |
With CKD | PEG | 5201 | 194 (3.7) | – | – | – | – | 788 | 22 (2.8) | – | – |
Sodium phosphate | 791 | 22 (2.8) | 0.74 | 0.48–1.15 | 0.91 | 0.58–1.42 | 788 | 22 (2.8) | 1.00 | 0.55–1.80 | |
≥60 y | PEG | 198,486 | 989 (0.5) | – | – | – | – | 45,803 | 172 (0.4) | – | – |
Sodium phosphate | 45,895 | 152 (0.3) | 0.67 | 0.56–0.79 | 0.83 | 0.70–0.99 | 45,803 | 152 (0.3) | 0.88 | 0.71–1.10 | |
With diabetes | PEG | 68,371 | 558 (0.8) | – | – | – | – | 15,101 | 99 (0.7) | – | – |
Sodium phosphate | 15,117 | 74 (0.5) | 0.60 | 0.47–0.76 | 0.77 | 0.60–0.98 | 15,101 | 73 (0.5) | 0.74 | 0.54–1.00 | |
With kidney stones | PEG | 7969 | 45 (0.6) | – | – | – | – | 2202 | 13 (0.6) | – | – |
Sodium phosphate | 2210 | 10 (0.5) | 0.80 | 0.41–1.60 | 1.01 | 0.49–2.07 | 2202 | 10 (0.5) | 0.77 | 0.34–1.76 | |
Hypercalciuria | PEG | 1864 | 10 (0.5) | – | – | – | – | 547 | 2 (0.4) | – | – |
Sodium phosphate | 558 | 5 (0.9) | 1.67 | 0.57–4.88 | 2.80 | 0.84–9.29 | 547 | 5 (0.9) | 2.50 | 0.49–12.89 | |
On NSAIDs | PEG | 118,078 | 408 (0.4) | – | – | – | – | 33,300 | 77 (0.2) | – | – |
Sodium phosphate | 33,321 | 73 (0.2) | 0.63 | 0.49–0.81 | 0.84 | 0.65–1.08 | 33,300 | 73 (0.2) | 0.95 | 0.69–1.31 | |
On thiazides | PEG | 108,878 | 564 (0.5) | – | – | – | – | 28,433 | 126 (0.4) | – | – |
Sodium phosphate | 28,468 | 96 (0.3) | 0.65 | 0.52–0.81 | 0.82 | 0.66–1.02 | 28,433 | 95 (0.3) | 0.75 | 0.58–0.95 |
NSAID, nonsteroidal anti-inflammatory drug.